TAQ-588

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTAQ-588
Drug Alias NameTAQ-588
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTumor necrosis factor α inhibitorsInterleukin-4 receptors inhibitors
TargetsInterleukin-4 receptorsTumor necrosis factor α
Therapy Area/IndicationsRejection of organ transplantationImmune System DiseasesDiabetes Mellitus +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCelldex Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelldex Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationImmune System DiseasesDiabetes Mellitus +[6] 

Other Information

ATC CodeN/A
Related LinksN/A